These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18094422)

  • 1. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
    van Erp NP; Gelderblom H; Karlsson MO; Li J; Zhao M; Ouwerkerk J; Nortier JW; Guchelaar HJ; Baker SD; Sparreboom A
    Clin Cancer Res; 2007 Dec; 13(24):7394-400. PubMed ID: 18094422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
    Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
    Connolly RM; Rudek MA; Garrett-Mayer E; Jeter SC; Donehower MG; Wright LA; Zhao M; Fetting JH; Emens LA; Stearns V; Davidson NE; Baker SD; Wolff AC
    Breast Cancer Res Treat; 2011 May; 127(1):153-62. PubMed ID: 21350820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of imatinib.
    Peng B; Lloyd P; Schran H
    Clin Pharmacokinet; 2005; 44(9):879-94. PubMed ID: 16122278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
    Filppula AM; Laitila J; Neuvonen PJ; Backman JT
    Br J Pharmacol; 2012 Apr; 165(8):2787-98. PubMed ID: 22014153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
    Gardner ER; Burger H; van Schaik RH; van Oosterom AT; de Bruijn EA; Guetens G; Prenen H; de Jong FA; Baker SD; Bates SE; Figg WD; Verweij J; Sparreboom A; Nooter K
    Clin Pharmacol Ther; 2006 Aug; 80(2):192-201. PubMed ID: 16890580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
    Kasserra C; Sansone-Parsons A; Keung A; Tetteh E; Assaf M; O'Mara E; Marbury T
    Clin Pharmacokinet; 2010 Jun; 49(6):397-406. PubMed ID: 20481650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
    Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
    Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.